Overview
SCYX market data
Price History
SCYX price chart · 1M
- O
- 5.58
- H
- 5.58
- L
- 5.43
- C
- 5.52
- Vol
- 896.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $5.58
- Previous Close
- $5.70
- Day High
- $5.58
- Day Low
- $5.43
- 52 Week High
- $8.20
- 52 Week Low
- $3.54
- 7 Day Return
- +5.24%
- 30 Day Return
- +52.28%
- 90 Day Return
- -2.80%
- 1 Year Return
- -25.81%
- Daily Notional Volume
- $4.9K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.06 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -41.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.53 – $10.48 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $50.9M · P/B 0.54 · P/S 2.47.
Company News
Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $33Benzinga · Aug 13, 2026, 2:14 PM
UPDATE: SCYNEXIS Q2 Adj. EPS $(0.57) Misses $(0.51) Estimate, Sales $235.000K Beat $80.330K EstimateBenzinga · Aug 10, 2026, 10:31 PM
SCYNEXIS Q2 EPS $0.63 Beats $(0.64) Estimate, Sales $235.000K Beat $80.330K EstimateBenzinga · Aug 10, 2026, 8:45 PM
Watching SCYNEXIS; Shares Trading Higher, Hearing GSK Is Close To Relaunching BREXAFEMME With The Co, FDA Updates BREXAFEMME Label With Pediatric Use Information And Revised Patient Safety GuidanceBenzinga · Jul 31, 2026, 4:04 PM
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing RegimensBenzinga · Jun 30, 2026, 12:05 PM
8-K filing — SCYNEXIS INC (SCYX)SEC EDGAR · Jun 26, 2026, 8:01 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jun 1, 2026, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News PendingBenzinga · May 29, 2026, 11:50 PM